At RSNA 2023 in Chicago, Dr. Busch presented on the retrospective analysis of MRI-guided transurethral ultrasound ablation (TULSA) in prostate cancer lesions at the extreme apex.

The clinical findings show TULSA is a promising prostate cancer treatment with minimal impact on urinary continence for thermal ablation of extreme apical lesions.

With a prostatectomy, the urologist is unable to see the difference between the apex of the prostate and the external sphincter. If a patient has an apical lesion and it is too close to the external sphincter, two things can happen:

  1. The urologist cuts out too much of the apex and the external sphincter and patients will chronically leak urine. The patient will have to wear a pad or a diaper and may need surgery to insert an artificial sphincter in an attempt to stop the constant urine flow.
  2. The urologist cuts across the tumor margin and leaves tumor behind, resulting in the man having to have radiation six weeks after his prostatectomy. 50% of these men will leak urine and can get a urethral stricture from the radiation.

Read the full paper to learn more about why TULSA Procedure is a safer, more effective alternative to prostatectomy surgery and other prostate cancer treatments.

Busch Center is proud to be the #1 private clinic in North America, and #2 in the world, offering the TULSA Procedure for treating prostate cancer and BPH.